Lisa M. McLennan

The paper presents an interim analysis of a canine cancer screening study using NGS-based liquid biopsy, showing increased preclinical cancer detection with OncoK9(R) testing.

This study evaluates a next-generation sequencing-based liquid biopsy test for detecting residual disease and monitoring cancer recurrence in dogs, finding it can identify recurrence earlier than clinical assessment.

This study shows that blood-based liquid biopsy using next-generation sequencing can detect genomic alterations in dogs with cancer, matching tumor tissue findings and identifying alterations from spatially separated tumor sites.